Polydex Pharmaceuticals Limited (POLXF-NASDAQ)
Interview with: George G. Usher, Chairman, President and CEO
Business News, Financial News, Stocks, Money & Investment Ideas, CEO Interview
and Information on their Ushercell product, which is in clinical trials for use as an anti-HIV and as a contraceptive.

Cover Story

CEOCFO Current Issue

Cover Story Archives

Private Equity Review

CEOCFO Interview Index

Future Features

Analyst Interviews

Corporate Financials

Contact & Ordering

This is a printer friendly page!

Polydex Pharmaceuticals’ Ushercell product in Phase III for HIV and Phase II clinical trials as a contraceptive, is an entry inhibitor that is not absorbed by the body, minimizing the chance of side effects



Healthcare
(POLXF-NASDAQ)

Polydex Pharmaceuticals Limited


George G. Usher
Chairman, President and CEO

Interview conducted by:
Walter Banks, Publisher
CEOCFOinterviews.com
December 1, 2005

Special one year trial subscription offer - only $59.00!
To order the complete Current Issue of CEOCFOinterviews.com and receive each complete issue e-mailed to your desktop for 12 months-left click below for our forms:

Purchase NOW!

There is a $59.00 charge for your one year trial subscription!
You will be emailed an invoice for Credit Card payment, followed by your ordered Current Issue !

disclaimers

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.

“It is a bit difficult to explain when you mention one product that acts as a contraceptive, anti-STD, herpes, gonorrhea, Chlamydia as well as anti-HIV. It sounds like snake oil; how can one product possible do all this? By its nature, Ushercell is a very viscous material and so in the contraceptive application it will significantly reduce the mobility of sperm. It inactivates them, it does not kill them. It inactivates them so that they cannot bind with the ovum and result in a pregnancy. As far as the anti-STDs in general, although it is not safe to generalize, to be brief, it seems to inactivate them. We believe that by attacking the outer coat or casing of the virus, we could thereby inactivate it.” - George G. Usher

Newsflash!

To view Releases highlight & left click on the company name!